219 related articles for article (PubMed ID: 24327292)
21. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Das R; Teitelbaum A; Garrison J; Kashala O; Chatterjee SK; Bhattacharya-Chatterjee M
J Clin Oncol; 1999 Sep; 17(9):2889-5. PubMed ID: 10561367
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
Conry RM; Khazaeli MB; Saleh MN; Allen KO; Barlow DL; Moore SE; Craig D; Arani RB; Schlom J; LoBuglio AF
Clin Cancer Res; 1999 Sep; 5(9):2330-7. PubMed ID: 10499601
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
25. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
Gulley JL; Madan RA; Tsang KY; Arlen PM; Camphausen K; Mohebtash M; Kamrava M; Schlom J; Citrin D
Expert Opin Biol Ther; 2011 Nov; 11(11):1409-18. PubMed ID: 21871012
[TBL] [Abstract][Full Text] [Related]
26. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
Farsaci B; Higgins JP; Hodge JW
Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
[TBL] [Abstract][Full Text] [Related]
27. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Osada T; Berglund P; Morse MA; Hubby B; Lewis W; Niedzwiecki D; Yang XY; Hobeika A; Burnett B; Devi GR; Clay TM; Smith J; Kim Lyerly H
Cancer Immunol Immunother; 2012 Nov; 61(11):1941-51. PubMed ID: 22488274
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
29. A carcinoembryonic antigen polynucleotide vaccine for human clinical use.
Conry RM; LoBuglio AF; Loechel F; Moore SE; Sumerel LA; Barlow DL; Pike J; Curiel DT
Cancer Gene Ther; 1995 Mar; 2(1):33-8. PubMed ID: 7621253
[TBL] [Abstract][Full Text] [Related]
30. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
[TBL] [Abstract][Full Text] [Related]
31. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
32. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Zhu MZ; Marshall J; Cole D; Schlom J; Tsang KY
Clin Cancer Res; 2000 Jan; 6(1):24-33. PubMed ID: 10656428
[TBL] [Abstract][Full Text] [Related]
33. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
34. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
Fong L; Hou Y; Rivas A; Benike C; Yuen A; Fisher GA; Davis MM; Engleman EG
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8809-14. PubMed ID: 11427731
[TBL] [Abstract][Full Text] [Related]
35. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
[TBL] [Abstract][Full Text] [Related]
36. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.
Liu KJ; Chao TY; Chang JY; Cheng AL; Ch'ang HJ; Kao WY; Wu YC; Yu WL; Chung TR; Whang-Peng J
J Biomed Sci; 2016 Aug; 23(1):64. PubMed ID: 27558635
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
Diaz CM; Chiappori A; Aurisicchio L; Bagchi A; Clark J; Dubey S; Fridman A; Fabregas JC; Marshall J; Scarselli E; La Monica N; Ciliberto G; Montero AJ
J Transl Med; 2013 Mar; 11():62. PubMed ID: 23497415
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
39. Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.
McCann KJ; Mander A; Cazaly A; Chudley L; Stasakova J; Thirdborough S; King A; Lloyd-Evans P; Buxton E; Edwards C; Halford S; Bateman A; O'Callaghan A; Clive S; Anthoney A; Jodrell DI; Weinschenk T; Simon P; Sahin U; Thomas GJ; Stevenson FK; Ottensmeier CH
Clin Cancer Res; 2016 Oct; 22(19):4827-4836. PubMed ID: 27091407
[TBL] [Abstract][Full Text] [Related]
40. Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R
J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
